EKErnesto Korbenfeld

Ernesto Korbenfeld

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ernesto Korbenfeld has a total of 96 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Tables S1-S2 from Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA

    by Nobuaki Matsubara, Johann de Bono, David Olmos, Giuseppe Procopio, Satoru Kawakami, Yüksel Ürün, Robbert van Alphen, Aude Flechon, Michael A. Carducci, Young Deuk Choi, et al.

    Supplementary data presenting additional demographic data and safety analysis.

  • Open Access

    Data from Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA

    by Nobuaki Matsubara, Johann de Bono, David Olmos, Giuseppe Procopio, Satoru Kawakami, Yüksel Ürün, Robbert van Alphen, Aude Flechon, Michael A. Carducci, Young Deuk Choi, et al.

    Purpose:The phase III PROfound study (NCT02987543) evaluated olaparib versus abiraterone or enzalutamide (control) in metastatic castration-resistant prostate cancer (mCRPC) with tumor homologous recombination repair (HRR) gene alterations. We present exploratory analyses on the use of circulating tumor DNA (ctDNA) testing as an additional method to identify patients with mCRPC with HRR gene alterations who may be eligible for olaparib treatment.Patients and Methods:Plasma samples collected during screening in PROfound were retrospectively sequenced using the FoundationOne®Liquid CDx test for BRCA1, BRCA2 (BRCA), and ATM alterations in ctDNA. Only patients from Cohort A (BRCA/ATM alteration positive by tissue testing) were evaluated. We compared clinical outcomes, including radiographic progression-free survival (rPFS) between the ctDNA subgroup and Cohort A.Results:Of the 181 (73.9%) Cohort A patients who gave consent for plasma sample ctDNA testing, 139 (76.8%) yielded a result and BRCA/ATM alterations were identified in 111 (79.9%). Of these, 73 patients received olaparib and 38 received control. Patients’ baseline demographics and characteristics, and the prevalence of HRR alterations were comparable with the Cohort A intention-to-treat (ITT) population. rPFS was longer in the olaparib group versus control [median 7.4 vs. 3.5 months; hazard ratio (HR), 0.33; 95% confidence interval (CI), 0.21–0.53; nominal P < 0.0001], which is consistent with Cohort A ITT population (HR, 0.34; 95% CI, 0.25–0.47).Conclusions:When tumor tissue testing is not feasible or has failed, ctDNA testing may be a suitable alternative to identify patients with mCRPC carrying BRCA/ATM alterations who may benefit from olaparib treatment.

  • Open Access

    Evaluación del tratamiento de primera línea en el carcinoma renal células claras en la Argentina

    by Federico Cayol, Gabriela Gatica, Pablo Companys, Carolina Passarella, Rodrigo Sanchez, Ernesto Korbenfeld, Juan José Zarbá, Omar Carranza, Rubén Kowalyszyn, Gonzalo Taetti, et al.

    El carcinoma renal de células claras es una de las neoplasias más frecuentes del tracto urinario, representando el 2-3% de los tumores malignos del adulto. La incidencia en los países latinoamericanos se encuentra en aumento. En Argentina, es el quinto tumor más frecuente, con más de 2,000 nuevos casos cada año, siendo un problema de salud pública considerable. A pesar de los avances terapéuticos, el pronóstico de los pacientes con enfermedad metastásica continúa siendo relativamente pobre. En años recientes, hubo un cambió en el estándar de tratamiento de primera línea de estos tumores, de esquemas con monodroga paso a tratamientos combinados. Debido al beneficio en prolongar la tasa de respuesta (TR), la supervivencia libre de progresión (SLP) y la supervivencia global (SG) en estudios fase III. Sin embargo, algunos expertos consideran que estos estudios tienen baja validez externa, ya que seleccionan a los pacientes más sanos, con escasas comorbilidades y muy buen estado general. Por otro lado, el porcentaje de pacientes latinoamericanos incluidos en los estudios pivótales, estaba subrepresentado. Por lo que tenemos pocos datos de la eficacia de estas nuevas combinaciones en nuestra población de pacientes. En contraste, los estudios del mundo real representan a un grupo de pacientes más heterogéneo, menos seleccionados, volviéndose esenciales para evaluar la efectividad de las nuevas intervenciones médicas. Por este motivo realizamos un estudio retrospectivo para evaluar los patrones de tratamiento y eficacia en 689 pacientes con CRcc metastásicos en la Argentina. Conclusiones: El acceso a los tratamientos combinados en los pacientes con CRcc metastásicos en la Argentina ha aumentado en el tiempo, llegando al 87% de los pacientes en el período 2021-2022. En esta cohorte retrospectiva se observó que los tratamientos combinados prolongaron la TR y SLP. Consideramos que esta información debe apoyar políticas públicas para garantizar el acceso a los tratamientos combinados a toda nuestra población de pacientes.

  • Open Access

    Trastuzumab-emtansine versus other anti-HER2 regimens in early or unresectable or metastatic HER2 positive breast cancer: systematic review and network meta-analysis

    by Agustín Ciapponi, Ariel Bardach, Carla Colaci, Federico Rodríguez Cairoli, Fernando Argento, Ernesto Korbenfeld, Sebastián García Martí

    Objective. We aimed to study the efficacy and safety of trastuzumab-emtansine (T-DM1) versus other anti-HER2therapies in HER2+ breast cancer (BC). Materials and Methods. We performed a network meta-analysis (NMA) of randomized controlled trials (RCTs). Our study focused on patients undergoing treatment for unresectable locally advanced breast cancer (LABC) or metastatic breast cancer (mBC), which included regimens involving trastuzumab and taxanes. Additionally, we considered cases within the first 6 months of treatment for HER2+ early breast cancer (EBC). Results. A total of 23 RCTs and 41 reports were included in our analysis. LABC and mBC showed no statistically significant difference in any of the comparisons of T-DM1 versus the other anti-HER2+ therapies. When assessing progression-free survival (PFS), trastuzumab-deruxtecan (T-DXd) and PyroCap demonstrated greater efficacy compared to other treatments (Hazard Ratio [HR]: 3.57; 95% confidence interval [CI]: 2.75-4.63 and HR: 1.82; 95% CI: 1.35-2.44;respectively), while T-DM1 alone exhibited superior effectiveness compared to LapCap (HR: 0.65; 95% CI: 0.55-0.77), TrasCap (HR: 0.65; 95% CI: 0.46-0.91), LapCapCitu (HR: 0.60; 95% CI: 0.33-1.10), Nera (HR: 0.55; 95% CI: 0.39-0.77), and Cap (HR: 0.37; 95% CI: 0.28-0.49). Conclusions. NMA allows a ranking based on the comparative efficacy and safety among the interventions available. Although superior to other schemes, T-DM1 showed a lower efficacy performancein PFS and overall response rate and a trend towards worse overall survival than T-DXd.


  • Top Cited Papers

    Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial

    by Joaquin Mateo, Johann S. de Bono, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, Kim N. Chi, Neeraj Agarwal, David Olmos, Antoine Thiery-Vuillemin, et al.

    Olaparib improved PFS and OS across subgroups of BRCA1/2mut #prostatecancer patients in the PROFOUND phase III trial.


  • Open Access

    Supplementary Tables S1-S2 from Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA

    by Nobuaki Matsubara, Johann de Bono, David Olmos, Giuseppe Procopio, Satoru Kawakami, Yüksel Ürün, Robbert van Alphen, Aude Flechon, Michael A. Carducci, Young Deuk Choi, et al.

    Supplementary data presenting additional demographic data and safety analysis.

  • Open Access

    Supplementary Tables S1-S2 from Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA

    by Nobuaki Matsubara, Johann de Bono, David Olmos, Giuseppe Procopio, Satoru Kawakami, Yüksel Ürün, Robbert van Alphen, Aude Flechon, Michael A. Carducci, Young Deuk Choi, et al.

    Supplementary data presenting additional demographic data and safety analysis.

  • Open Access

    Data from Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA

    by Nobuaki Matsubara, Johann de Bono, David Olmos, Giuseppe Procopio, Satoru Kawakami, Yüksel Ürün, Robbert van Alphen, Aude Flechon, Michael A. Carducci, Young Deuk Choi, et al.

    Purpose:The phase III PROfound study (NCT02987543) evaluated olaparib versus abiraterone or enzalutamide (control) in metastatic castration-resistant prostate cancer (mCRPC) with tumor homologous recombination repair (HRR) gene alterations. We present exploratory analyses on the use of circulating tumor DNA (ctDNA) testing as an additional method to identify patients with mCRPC with HRR gene alterations who may be eligible for olaparib treatment.Patients and Methods:Plasma samples collected during screening in PROfound were retrospectively sequenced using the FoundationOne®Liquid CDx test for BRCA1, BRCA2 (BRCA), and ATM alterations in ctDNA. Only patients from Cohort A (BRCA/ATM alteration positive by tissue testing) were evaluated. We compared clinical outcomes, including radiographic progression-free survival (rPFS) between the ctDNA subgroup and Cohort A.Results:Of the 181 (73.9%) Cohort A patients who gave consent for plasma sample ctDNA testing, 139 (76.8%) yielded a result and BRCA/ATM alterations were identified in 111 (79.9%). Of these, 73 patients received olaparib and 38 received control. Patients’ baseline demographics and characteristics, and the prevalence of HRR alterations were comparable with the Cohort A intention-to-treat (ITT) population. rPFS was longer in the olaparib group versus control [median 7.4 vs. 3.5 months; hazard ratio (HR), 0.33; 95% confidence interval (CI), 0.21–0.53; nominal P < 0.0001], which is consistent with Cohort A ITT population (HR, 0.34; 95% CI, 0.25–0.47).Conclusions:When tumor tissue testing is not feasible or has failed, ctDNA testing may be a suitable alternative to identify patients with mCRPC carrying BRCA/ATM alterations who may benefit from olaparib treatment.

  • Open Access

    Miocardiopatía por estrés asociada a quimioterapia

    by Martín Naveira, Santiago Corsico, Lucas Datri, Laura Mendez, Victoria Faura, Mauro Dutto, Alfredo Romero, Luciana Bella Quero, Ernesto Korbenfeld, Cintia Novas, et al.

    La miocardiopatía por estrés es una enfermedad infrecuente caracterizada por dolor precordial típico, elevación de las enzimas cardíacas y cambios electrocardiográficos, sin evidencia de enfermedad coronaria. Es transitoria y no tiene una causa clara desencadenante, aunque el estrés emocional es un factor que pareciera estar involucrado en la mayoría de los casos comunicados. Como consecuencia del desarrollo diagnóstico de enfermedades cardiovasculares, en los últimos 15 años aumentaron los casos, representando entre el 1-2% de los pacientes que se presentan con dolor precordial y cambios en el electrocardiograma. La toxicidad cardiológica por la quimioterapia y otros agentes antineoplásicos es conocida, pero el síndrome de takotsubo asociado a quimioterapia es poco frecuente y sólo se registran informes de casos. Presentamos tres pacientes con miocardiopatía por estrés asociado a quimioterapia.

  • Open Access

    Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2 , or ATM Alterations Identified by Testing Circulating Tumor DNA

    by Nobuaki Matsubara, Johann de Bono, David Olmos, Giuseppe Procopio, Satoru Kawakami, Yüksel Ürün, Robbert van Alphen, Aude Flechon, Michael A. Carducci, Young Deuk Choi, et al.

    Purpose: The phase III PROfound study (NCT02987543) evaluated olaparib versus abiraterone or enzalutamide (control) in metastatic castration-resistant prostate cancer (mCRPC) with tumor homologous recombination repair (HRR) gene alterations. We present exploratory analyses on the use of circulating tumor DNA (ctDNA) testing as an additional method to identify patients with mCRPC with HRR gene alterations who may be eligible for olaparib treatment. Patients and Methods: Plasma samples collected during screening in PROfound were retrospectively sequenced using the FoundationOne®Liquid CDx test for BRCA1, BRCA2 (BRCA), and ATM alterations in ctDNA. Only patients from Cohort A (BRCA/ATM alteration positive by tissue testing) were evaluated. We compared clinical outcomes, including radiographic progression-free survival (rPFS) between the ctDNA subgroup and Cohort A. Results: Of the 181 (73.9%) Cohort A patients who gave consent for plasma sample ctDNA testing, 139 (76.8%) yielded a result and BRCA/ATM alterations were identified in 111 (79.9%). Of these, 73 patients received olaparib and 38 received control. Patients’ baseline demographics and characteristics, and the prevalence of HRR alterations were comparable with the Cohort A intention-to-treat (ITT) population. rPFS was longer in the olaparib group versus control [median 7.4 vs. 3.5 months; hazard ratio (HR), 0.33; 95% confidence interval (CI), 0.21–0.53; nominal P < 0.0001], which is consistent with Cohort A ITT population (HR, 0.34; 95% CI, 0.25–0.47). Conclusions: When tumor tissue testing is not feasible or has failed, ctDNA testing may be a suitable alternative to identify patients with mCRPC carrying BRCA/ATM alterations who may benefit from olaparib treatment.